The 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Coadministered With DTPw-HBV/Hib and Poliovirus Vaccines: Assessment of Immunogenicity
Authors:
- Leszek SzenbornLSLeszek Szenborn
- Andrzej ChrobotACAndrzej Chrobot
- Edison AlbertoEAEdison Alberto
- Patricia LommelPLPatricia Lommel
- Salvacion GatchalianSGSalvacion Gatchalian
- Ilse DieussaertIDIlse Dieussaert
- Lode SchuermanLSLode Schuerman
- 1 April 2009
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 28 (4) , S89-S96
Abstract
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was evaluated when coadministered with DTPw-HBV/Hib and OPV at 6, 10, and 14 weeks of age in the Philippines, or with DTPw-HBV/Hib and IPV at 2, 4, and 6 months of age in Poland. In this double-blind, controlled study (107007/NCT00344318), 400 Filipino and 406 Polish infants 6 to 12 weeks of age were randomized (3:1) to receive either PHiD-CV or the 7-valent pneumococcal conjugate vaccine (7vCRM). Immune responses were assessed 1 month post-dose III. Percentages of infants with anti-pneumococcal antibody concentrations >or=0.2 microg/mL (GSK's 22F-inhibition ELISA) were within the same range for both pneumococcal conjugate vaccine groups, with the exception of serotypes 6B and 23F for which lower percentages were observed in the PHiD-CV group in Poland. At least 98.2% of PHiD-CV vaccinees had antibody concentrations >or=0.2 microg/mL against pneumococcal serotypes 1, 5, and 7F. In both countries, anti-pneumococcal antibody geometric mean concentrations against serotypes 18C and 19F were higher in the PHiD-CV group than in the 7vCRM group. Antibody geometric mean concentrations for most of the other common serotypes were within the same range for both groups in the Philippines and were lower in the PHiD-CV group in Poland. Functional responses (opsonophagocytic activity [OPA]) were observed for all vaccine serotypes in both countries. PHiD-CV was immunogenic against each of the 10 pneumococcal vaccine serotypes when coadministered with DTPw-HBV/Hib and poliovirus vaccines.Keywords
This publication has 19 references indexed in Scilit:
- Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccinesExpert Opinion on Biological Therapy, 2008
- Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in childrenVaccine, 2007
- Critical Differences between Pneumococcal Polysaccharide Enzyme-Linked Immunosorbent Assays with and without 22F Inhibition at Low Antibody Concentrations in Pediatric SeraClinical and Vaccine Immunology, 2006
- Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccineInternational Journal of Infectious Diseases, 2003
- Pneumococcal Type 22F Polysaccharide Absorption Improves the Specificity of a Pneumococcal-Polysaccharide Enzyme-Linked Immunosorbent AssayClinical and Diagnostic Laboratory Immunology, 2001
- Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in EnglandThe Lancet, 2001
- Worldwide Haemophilus influenzae Type b Disease at the Beginning of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the Polysaccharide Vaccine and a Decade after the Advent of ConjugatesClinical Microbiology Reviews, 2000
- Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in childrenThe Pediatric Infectious Disease Journal, 2000
- Rational Design of Conjugate VaccinesPediatric Research, 1992
- Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61 080 childrenThe Pediatric Infectious Disease Journal, 1991